Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accumulated Expenses (2021 - 2025)

Aligos Therapeutics' Accumulated Expenses history spans 5 years, with the latest figure at $7.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 16.86% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, up 16.86%, while the annual FY2025 figure was $7.5 million, 16.86% up from the prior year.
  • Accumulated Expenses reached $7.5 million in Q4 2025 per ALGS's latest filing, up from $5.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.8 million in Q4 2023 to a low of $3.1 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $8.8 million, with a median of $7.2 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: plummeted 75.54% in 2023, then surged 290.37% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $6.3 million in 2021, then surged by 153.42% to $16.0 million in 2022, then increased by 5.01% to $16.8 million in 2023, then tumbled by 62.08% to $6.4 million in 2024, then grew by 16.86% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Accumulated Expenses are $7.5 million (Q4 2025), $5.3 million (Q3 2025), and $12.2 million (Q2 2025).